Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Ltd. - Ordinary Shares (NQ:ENLV)

4.640 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.640
Bid (Size) 4.250 (400)
Ask (Size) 6.290 (2,000)
Prev. Close 4.640
Today's Range 4.640 - 4.640
52wk Range 0.4277 - 7.640
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
From Enlivex Ltd.
Via GlobeNewswire

Performance

YTD
+514.7%
+514.7%
1 Month
+644.8%
+644.8%
3 Month
+429.7%
+429.7%
6 Month
+373.5%
+373.5%
1 Year
+289.9%
+289.9%

More News

Read More
News headline image
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025
Via NewMediaWire
News headline image
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
From Enlivex Ltd.
Via GlobeNewswire
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
From Enlivex Ltd.
Via GlobeNewswire
News headline image
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Enlivex Ltd. - Ordinary Shares publicly traded?
Yes, Enlivex Ltd. - Ordinary Shares is publicly traded.
What exchange does Enlivex Ltd. - Ordinary Shares trade on?
Enlivex Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Enlivex Ltd. - Ordinary Shares?
The ticker symbol for Enlivex Ltd. - Ordinary Shares is ENLV on the Nasdaq Stock Market
What is the current price of Enlivex Ltd. - Ordinary Shares?
The current price of Enlivex Ltd. - Ordinary Shares is 4.640
When was Enlivex Ltd. - Ordinary Shares last traded?
The last trade of Enlivex Ltd. - Ordinary Shares was at 07/20/26 04:00 PM ET
What is the market capitalization of Enlivex Ltd. - Ordinary Shares?
The market capitalization of Enlivex Ltd. - Ordinary Shares is 84.94M
How many shares of Enlivex Ltd. - Ordinary Shares are outstanding?
Enlivex Ltd. - Ordinary Shares has 85M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.